XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Jun. 30, 2018
Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (16,910,533) $ (9,369,401)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 485,710 476,103
Share-based payments for services 349,319 151,611
Share-based payments for interest 80,716 0
Equity based compensation 2,193,402 1,002,923
Common stock contributed to 401(k) plan 109,073 114,483
Shares issued for settlement of clinical research costs 2,957,400 0
Loss on prepaid research and development 471,157 0
Loss on retired equipment 0 1,187
Gain on derivative instruments (187,967) (9,669,977)
Amortization of debt discount 1,956,424 21,441
Inducement expense 291,234 0
Capitalized lease interest 125,044 149,209
(Increase)/decrease in assets:    
Receivables 98,829 (182,563)
Prepaid expenses 122,627 275,084
Inventory used for R&D and manufacturing 44,364 350,904
Deposits 150,000 154,995
Increase/(decrease) in liabilities:    
Accounts payable (1,960,438) 5,514,909
Accrued expenses (74,856) 555,250
Due to employees 548,982 103,013
Other liabilities 4,819 490
Net cash used in operating activities (9,144,694) (10,350,339)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment (1,015) (10,525)
Expenditures for patent costs (2,437) 0
Net cash used in investing activities (3,452) (10,525)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock and warrants 6,996,763 7,167,773
Proceeds from issuance of notes payable 0 1,510,000
Proceeds from exercise of warrants 2,133,677 0
Payments on obligations under capital lease (5,082) (2,428)
Net cash provided by financing activities 9,125,358 8,675,345
NET DECREASE IN CASH AND CASH EQUIVALENTS (22,788) (1,685,519)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 2,369,438 2,917,996
CASH AND CASH EQUIVALENTS, END OF PERIOD 2,346,650 1,232,477
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Decrease in receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services 0 305,341
Capitalizable patent costs included in accounts payable 61,501 11,586
Capital lease obligation included in accounts payable 408 2,266
Property and equipment acquired through capital lease 0 26,104
Fair value of warrants issued in connection with public offering 0 4,665,683
Exercise of derivative liabilities 784,119 0
Discount on notes payable 0 (1,205,647)
Financing costs included in accounts payable 0 92,467
Prepaid consulting services paid with issuance of common stock 113,786 (37,550)
Notes payable converted into common shares 2,294,300 0
Conversion of accrued salaries and board fees to notes payable 0 250,000
Cash paid for interest expense $ 1,312,664 $ 1,413,455